Madam .... From MSB's perspective its about receiving the $$ and also partnering with a Pharma that is passionate about MPC's and also having capable distribution and sales team.
MNK is a $4.8bn mkt cap company with $3m bn sales turnover.
As you were not around at the time, let me help you understand that CEPH (Dec 2010) was a $3.5bn mkt cap company with a $2.5bn turnover at the time. History will tell you CEPH paid $350M to Mesoblast in partnering Revacsor + cord blood ( plus $1.7bn on agreed milest0nes).
Here is an article at the time the deal occurred. Please read it for your own benefit.
http://www.genengnews.com/gen-news-...ialize-mesoblast-stem-cell-therapies/81244348
So given the similarities with CEPH ( a passionate and hungry Global Pharma) , in my view MNK would be an accomplished and adept partner with the financial capacity to deliver for MSB ....
.....are we about to experience Dec 2010 all over again ?
GLTAH
Madam .... From MSB's perspective its about receiving the $$ and...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.15 |
Change
0.025(2.22%) |
Mkt cap ! $1.313B | |||
| Open | High | Low | Value | Volume |
| $1.16 | $1.19 | $1.13 | $8.289M | 7.186M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 22569 | $1.14 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.15 | 105374 | 2 |
View Market Depth
| Last trade - 16.10pm 22/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.15 |
Change
0.025 ( 2.46 %) |
||||
| Open | High | Low | Volume | ||
| $1.16 | $1.19 | $1.13 | 1229288 | ||
| Last updated 15.59pm 22/05/2024 ? | |||||
| MSB (ASX) Chart |